v3.25.1
Summary of significant transactions - Gilead Collaboration Agreement (Details)
€ in Millions, $ in Millions
3 Months Ended 12 Months Ended
Jan. 08, 2025
item
Oct. 01, 2023
Aug. 23, 2019
EUR (€)
Aug. 23, 2019
USD ($)
Jul. 14, 2019
Dec. 31, 2023
Dec. 31, 2024
item
Aug. 23, 2019
USD ($)
Spin-off                
Summary Of Significant Transaction [line items]                
Number Of Entities Following Spin Off 2              
Gilead collaboration agreement                
Summary Of Significant Transaction [line items]                
Global Research And Development Collaboration Term         10 years      
Upfront Payment Received     € 3,569.8 $ 3,950        
Equity Investment from Gilead.     € 960.1         $ 1,100
Number of Performance Obligations             3  
Gilead collaboration agreement | Filgotinib drug license | Gilead                
Summary Of Significant Transaction [line items]                
Future global development cost sharing ratio before predetermined level           100.00%    
Gilead collaboration agreement | Filgotinib drug license | Original Agreement | Gilead                
Summary Of Significant Transaction [line items]                
Cost Share For Global Development Activities         25.00%      
Future global development cost sharing ratio before predetermined level         25.00%      
Gilead collaboration agreement | Filgotinib drug license | First Revised Agreement | Gilead                
Summary Of Significant Transaction [line items]                
Cost Share For Global Development Activities             50.00%  
Future global development cost sharing ratio before predetermined level             50.00%  
Gilead collaboration agreement | Filgotinib drug license | Second Revised Agreement | Gilead                
Summary Of Significant Transaction [line items]                
Future global development cost sharing ratio before predetermined level   100.00%